Decoy Therapeutics awarded Chief Business Officer Marschel Peter Klaus 3,900 shares at $0 per share on Aug. 31, 2026. For investors, the transaction establishes Klaus’s disclosed post-award ownership at 3,900 Decoy Therapeutics shares, connecting the executive award with his resulting Equity position.

Key Highlights

  • The transaction was dated Aug. 31, 2026.
  • The shares carried an award price of $0 per share.
  • Marschel Peter Klaus held 3,900 Decoy Therapeutics shares after the transaction.

Decoy Therapeutics Inc. (NASDAQ: DCOY) awarded 3,900 shares to Marschel Peter Klaus, its chief business officer, at $0 per share. The transaction dated Aug. 31, 2026, left Klaus with 3,900 Decoy Therapeutics shares.

Zero-Cost Award Dated Aug. 31, 2026

The equity award covered 3,900 shares of Decoy Therapeutics stock. The transaction date was Aug. 31, 2026. Klaus’s ownership following the award was 3,900 shares. The award and the resulting ownership figure are both tied to Marschel Peter Klaus.